— Know what they know.
Not Investment Advice

RAPT NASDAQ

RAPT Therapeutics, Inc.
1W: +0.1% 1M: +0.4% 3M: +80.8% YTD: +82.1% 1Y: +541.7% 3Y: -75.7% 5Y: -61.3%
$58.01
Last traded 2026-03-06 — delisted
NASDAQ · Healthcare · Biotechnology · $1.6B mcap · 8M float · 28.01% daily turnover · Short 46% of daily vol

Balance Sheet Trends

Total Assets
$240M +38.7% ▲
5Y CAGR: +23.2%
Total Liabilities
$50M +91.8% ▲
5Y CAGR: +34.4%
Shareholders Equity
$190M +29.2% ▲
5Y CAGR: +21.0%
Cash & Investments
$231M +45.4% ▲
5Y CAGR: +24.5%
Total Debt
$4M -35.0% ▼
Net Debt
-$165M -307.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$25M$24M$39M$47M$170M
Short-Term Investments$87M$166M$210M$111M$61M
Cash & ST Investments$112M$190M$249M$159M$231M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$4M$3M$4M$3M$4M
Total Current Assets$116M$193M$253M$162M$235M
Property, Plant & Equip.$3M$3M$9M$8M$5M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$389K$3M$4M$4M$389K
Total Non-Current Assets$3M$6M$14M$12M$5M
Total Assets$119M$199M$266M$173M$240M
— Liabilities —
Accounts Payable$2M$2M$3M$5M$1M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$4M$1M$0$0$0
Other Current Liabilities$2M$3M$5M$8M$7M
Total Current Liabilities$12M$10M$14M$22M$48M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$2M$2M$0$0$0
Total Non-Current Liabilities$3M$3M$7M$4M$2M
Total Liabilities$15M$12M$21M$26M$50M
— Equity —
Common Stock$2K$3K$3K$3K$13K
Retained Earnings-$215M-$284M-$368M-$485M-$615M
Accumulated OCI-$177K-$206K-$26K$103K$50K
Total Stockholders Equity$104M$186M$245M$147M$190M
Total Liabilities & Equity$119M$199M$266M$173M$240M
— Key Metrics —
Total Debt$0$0$9M$7M$4M
Net Debt-$25M-$24M-$30M-$41M-$165M
Total Investments$87M$166M$210M$111M$61M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms